Global Oncohematology Summit

Harmonizing testing in blood cancer care

The global burden of blood cancer is huge, with around 474,519 new cases of leukemia in 2020 alone – and 311,594 deaths (1). With an overall 5-year relative survival rate in the US of 66.4% for people diagnosed with all kinds of leukemia (2), this makes early diagnosis and treatment more important than ever.

But we still have so many challenges to overcome. How can we ensure better patient access to oncohematology testing? While many testing guidelines and recommendations are available, these rarely apply globally. What can we do to overcome the challenges that impact diagnosis, monitoring and patient care? Let’s unite together and pledge I Can – a decision that improves patients’ lives.

Count me in!

Global Oncohematology Summit 2023

On September 13 and 14, we will host our Global Oncohematology Summit. We will bring together global oncohematology experts to discuss the unmet needs and challenges in oncohematology testing and blood cancer clinical care and research. Our Global Oncohematology Summit is a free, educational virtual event.

Join us at this two-day virtual event to address current challenges and exchange ideas and insights in oncohematology testing and blood cancer clinical care and research. Plus, we will discuss the impact of the latest technological advances.

Our Global Oncohematology Summit is free to attend, purely educational and CME and CPD-accredited.

References:

1. Leukemia Fact Sheet, International Agency for Research on Cancer, World Health Organization, accessed July 4, 2023, https://gco.iarc.fr/today/data/factsheets/cancers/36-Leukaemia-fact-sheet.pdf

2. Leukemia & Lymphoma Society website, accessed July 4, 2023, https://www.lls.org/facts-and-statistics/facts-and-statistics-overview#Leukemia

“Educational programs such as this one are important because they communicate knowledge and ideas that could ultimately improve patient management and outcomes.”

Prof. Susan Branford
SA Pathology, Australia

Why attend

The Global Oncohematology Summit is a must-attend educational event. It brings together blood cancer clinical researchers, oncohematologists, data specialists and blood cancer survivors to exchange ideas and insights in oncohematology testing and blood cancer clinical care and research.

Event highlights:

Here’s a preview of what you can expect:

Educational presentations showcasing the latest in blood cancer patient therapies management and future perspectives
Expert views on the promise and future of CAR-T cell therapy and other breakthroughs in clinical practice
Advocate and patient perspectives, including one survivor’s journey to being 10 years’ cancer-free
New insights into testing and monitoring of blood cancers
A European diagnostic laboratory’s perspective on their IVDR strategy
Live panel discussion on the importance of treatment compliance and monitoring treatment response for patients
The chance to pose questions to the speakers and panel participants

Count me in

The Global Oncohematology Summit is CME and CPD-accredited*

By participating in the summit, you will earn CME credits and CPD certification (validated shortly after the event). That's two more good reasons to join us on September 13 and 14.
* Certification applied for.

Join us

Explore event details

Time (CET)	Session and speaker
13:00–13:10	Opening remarks from QIAGEN
13:10–13:50	Keynote lecture Review of the past, present and future of hematology Speaker: Prof. Elias Jabbour, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, USA
13:50–14:25	Presentation Monitoring patients: Value of sensitive and standardized testing Speaker: Prof. Susan Branford, SA Pathology, Royal Adelaide Hospital, Adelaide, Australia
14:25–15:00	Presentation CML: Molecular measurable residual disease in practice Speaker: Dr. Jean-Michel Cayuela, Laboratoire Central d’Hématologie, Hôpital Saint-Louis, Paris, France
15:00–15:45	Patient perspective A 23-year CML patient’s journey – from darkness to light Speaker: Giora Sharf
15:45–16:00	Coffee break
16:00–16:35	Presentation New insights into AML testing and monitoring Speaker: Prof. Giovanni Martinelli, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST IRCCS, Meldola, Italy
16:35–17:10	Presentation MRD testing in AML: Prime time in the clinic? Speaker: Dr. Michael Heuser, Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
17:10–17:55	Panel discussion Compliance with treatment and monitoring treatment response in patients Expert panel: Prof. Giovanni Martinelli, Dr. Jean-Michel Cayuela, Giora Sharf Moderator: Prof. Elias Jabbour
17:55–18:00	Closing remarks from QIAGEN

Time (CET)	Session and speaker
09:00–09:05	Opening remarks from QIAGEN
09:05–09:40	Presentation Comprehensive evaluation for risk classification and treatment selection for Ph- ALL Speaker: Dr. Nicola Gökbuget, University Hospital Frankfurt, Germany
09:40–10:15	Presentation MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL Speaker: Dr. Rathana Kim, Department of Molecular Hematology, Hematology Laboratory, Hôpital Saint-Louis, Paris, France
10:15–10:50	Presentation Importance of testing in multiple myeloma Speaker: Dr. Claudio Cerchione, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" – IRST IRCCS, Meldola, Italy
10:50–11:25	Presentation A conversation with Prof. Albrecht Stenzinger: IVDR strategy Speaker: Prof. Albrecht Stenzinger, Institute of Pathology, University Hospital Heidelberg, Germany
11:25–12:40	Lunch and networking
12:40–13:15	Presentation JAK2 V617F monitoring in MPN Speaker: Prof. Jean-Jacques Kiladjian, Clinical Investigations Center, Saint-Louis Hospital & the University of Paris, Paris, France
13:15–13:50	Presentation Using molecular testing to detect biomarker heterogeneity within MPN Speaker: Dr. Bruno Cassinat, Department of Cell Biology, Saint-Louis Hospital, Paris, France
13:50–14:25	Presentation Approaches to select patients for CAR T-cell therapy Speaker: Dr. Jae Hong Park, Memorial Sloan Kettering Cancer Center, New York, USA
14:25–15:10	Patient perspective A testimonial from a cancer survivor on CAR T-cell therapy Speaker: Tom Whitehead, Co-founder of the Emily Whitehead Foundation, Philipsburg, USA
15:10–15:25	Closing remarks from QIAGEN

Speaker	Session summary
Prof. Susan Branford 13:50–14:25	Monitoring patients: Value of sensitive and standardized testing I will discuss how standardisation of molecular testing was achieved for patients with chronic myeloid leukaemia and how this model could be applied for other blood cancers. Real-time quantitative PCR has been a gold standard for quantitative assessment of disease levels but digital PCR could provide additional benefits for the precise assessment of measurable residual disease.
Dr. Jean-Michel Cayuela 14:25–15:00	CML: Molecular measurable residual disease in practice In his talk Dr. ;Cayuela will discuss the use of measurable residual disease (MRD) in chronic myeloid leukemia (CML): methodologies for MRD assessment; clinical relevance and medical decision making on the basis of MRD; what patients need to know about MRD as it relates to their disease status and treatment. Finally, he will discuss ongoing challenges and future directions with the goal of optimizing MRD usage in CML patients management.
Giora Sharf 15:00–15:45	A 23-year CML patient’s journey – from darkness to light Giora Sharf will share his cancer journey from being diagnosed with chronic myeloid leukemia (CML) to being to being on a Treatment Free Remission (TFR) keeping his deep molecular response.. He was diagnosed in March 2000 at the age of 47. After the initial shock of the diagnosis and some research on treatment options, he elected to wait for a clinical trial with a new agent, STI571. He joined the IRIS trial in June 2000 with Prof Andreas Hochhaus in Germany, and after 7 months on interferon, he began taking Imatinib. After being PCR negative for 14 years he has stooped treatment more than 8 years ago and is on a Treatment Free Remission (TFR).
Dr. Michael Heuser 16:35–17:10	MRD testing in AML: Prime time in the clinic? In my presentation I will discuss the use of measurable residual disease (MRD) in acute myeloid leukemia (AML). I will review the different methodologies for MRD assessment, describe the clinical relevance and medical decision making based on MRD. Finally, I will discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management.

Speaker	Session summary
Dr. Nicola Gökbuget 09:05–09:40	Comprehensive evaluation for risk classification and treatment selection for Ph- ALL Dr. Gökbuget will review goals for risk stratification, different risk models and potential risk factors in the management of adult ALL.She will specifically focus on the role of minimal residual disease and other prognostic factors in Ph/BCR::ABL- negative ALL
Dr. Rathana Kim 09:40–10:15	MRD as a tool to evaluate treatment response and predict relapse in Ph+ ALL Minimal residual disease (MRD) represents the most reliable marker to predict outcome and guide therapeutic decision in acute lymphoblastic leukemia (ALL) management in both children and adults. In Philadelphia-positive (Ph+) ALL, molecular MRD assessments relies on two markers, the oncogenic fusion BCR::ABL1 and the genomic clono-specific immunoglobulin and T-cell receptor (IG/TR). The presentation will review methodologies and clinical settings using both approaches in modern therapy era.
Dr. Claudio Cerchione 10:15–10:50	Importance of testing in multiple myeloma The treatment of multiple myeloma has recently been revolutionized, thanks to the development of many new drugs and the addition of a new backbone, daratumumab, anti-CD38 monoclonal antibody, in frontline setting. In this scenario, the importance of testing accurately the results of the treatment, particularly evaluating MRD during the patient journey, is becoming more and more important, in order to optimize the use of the drugs, also in maintenance setting, and to balance correctly efficacy and toxicity. Considering the opportunities that we have, our aim, particularly in first lines of therapy, should be to achieve MRD negativity, which correlates with the best long-term outcome.
Dr. Bruno Cassinat 13:15–13:50	Using molecular testing to detect biomarker heterogeneity within MPN Myeloproliferative neoplasms (MPNs) are a group of chronic hematological disorders characterized by a high degree of heterogeneity in terms of clinical evolution and responses to treatments. From a molecular point of view, MPNs are also highly heterogeneous, with driver mutations found in 3 different genes and additional mutations found in dozens of genes. Recent methods such as next generation sequencing and single cell analysis allow better detecting and understanding the heterogeneity of these disorders.
Dr. Jae Hong Park 13:50–14:25	Approaches to select patients for CAR T-cell therapy In the last several years, we have observed emergence of several promising immunotherapeutic approaches in solid and hematologic malignancies. One of this approach involves a genetic modification of patient’s own T cells to express a chimeric antigen receptor (CAR) targeting a tumor-specific antigen. A CAR is a recombinant receptor construct composed of an antibody-derived single-chain variable fragment (scFv), linked to intracellular T-cell signaling domains of the T-cell receptor, thereby redirecting T-cell specificity to the tumor in an HLA-independent manner. In this talk, we will review the 1) generalized overview of clinical development of CD19 targeted CAR T cells in hematologic malignancies and lessons learned, 2) steps involved to ensure successful delivery of this product to patients, and 3) post-infusion monitoring strategies.

Download agenda

Don't miss this live-streamed educational event. Or, access it free on-demand at your convenience later.

Register now!

Speaker lineup and bios

Take the "I CAN" pledge by registering for this educational event

Register now